ABSTRACT Twenty-three structural analogs of the leukotriene components of slow reacting substance of anaphylaxis (SRS-A), in which the polar regions of the leukotriene were systematically modified, were tested for their contractile activities on guinea pig pulmonary parenchymal strips and guinea pig ileum. The structural modifications allowed evaluation of the separate contributions of the four polar units in the C-1 to C-6 region ofthe SRS-A leukotrienes to smooth muscle spasmogenic activity. The free NH2-terminal amino group of the S-linked peptide was necessary for full activity, and its deletion or substitution reduced activity by more than one but less than two orders of magnitude. A similar level of importance was apparent for the free glycine carboxyl group. In contrast, a free eicosanoid carboxyl at C-1 is not required for full activity on the airway and for substantial activity on the ileum. A role for the C-5 hydroxyl is indicated by the inactivity of the one available 5-desoxy analog. Nucleophilic, divalent sulfur is not critical to leukotriene D (LTD) activity, in that one sulfoxide had substantial function. The conformational relationship between the eicosanoid and peptide moieties of LTD is of considerable importance in that epimers at the C-5 or C-6 position were less active than LTD by more than two orders of magnitude. Several lines of evidence suggest that the relative geometrical arrangement of the C20 chain and the peptide unit is important to activity, consistent with the existence of a true receptor for LTD.
Each of the leukotriene constituents of slow reacting substance of anaphylaxis (SRS-A)-namely, 5-(S)-hydroxy-6(R)-S-glutathionyl-7,9-trans,11,14-cis-eicosatetraenoic acid (leukotriene C; LTC) and the 6-S-cysteinylglycyl (LTD) and 6-S-cysteinyl (LTE) analogs ( Fig. 1) (1-6)-has significant biological potency as a nonvascular smooth muscle spasmogen for guinea pig pulmonary parenchymal strips and guinea pig ileum (6, 7) . The likely role of these leukotrienes in immediate hypersensitivity reactions and the desirability of devising chemical agents that can function as antagonists prompted a study of the activity of synthetic leukotriene analogs chosen to provide structural information regarding the nature ofthe recognition site(s). A study of 16 leukotriene analogs, in which the principal alteration of structure was in the "W" portion of the eicosanoid chain (as opposed to the "carboxylic" end) revealed that, although a long hydrophobic chain is required for high activity, the degree of unsaturation and the geometry ofthe w end are not very critical (8) . We now report the comparative contractile activities of a series of23 additional SRS-A analogs in which the polar regions of the leukotriene system have been systematically modified. These variations are of five types: change in the peptide or amino acid substituent at C-6 of the eicosanoid chain, modification in the carboxylic groups of the eicosanoid and peptide moieties, removal or modification of free amino in the peptide section, oxidation of sulfur attached to C-6, and change in absolute chirality at C-5 or C-6. The results obtained allow an assessment of the structural discrimination of the recognition-function response and the condition of the ionizable leukotriene functional groups during binding.
MATERIALS AND METHODS
Synthesis of Leukotriene Analogs. The order ofpresentation in this section of the synthetic analogs is similar to that used in Table 1 ; the entry number from the table is indicated for each analog. Analogs in Table 1 are named relative to the parent leukotriene (LTC, LTD, or LTE). Leukotrienes C and D were prepared as described (2, 9) . They and all the other analogs used in this study were characterized by ultraviolet absorption; all compounds possessing the 7,9,11-triene system exhibited an ultraviolet maximum at 281.5-282 nm with shoulders at about 272 and 292 nm (in water or methanol solution except as noted). Each leukotriene analog was purified by reversed-phase highperformance liquid chromatography (RP-HPLC) as described (2) , and only purified, chromatographically homogeneous compounds were employed in the biological measurements. Retention volume (Rv) data refer to a Waters Associates C18 tkBondapak RP-HPLC column eluted with methanol/water, Abbreviations: SRS-A, slow reacting substance of anaphylaxis; LTC, leukotriene C; LTD, leukotriene D; LTE, leukotriene E; pen, penicillamine (1, (3dimethylcysteine); RP-HPLC, reversed-phase highperformance liquid chromatography; Rv, retention volume; LTA, leukotriene A; EC5o, amount required to give 50% of maximum response.
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Medical Sciences: Lewis et al. (9) with 15 M ammonium hydroxide/dimethyoxyethane, 1:1 (vol/vol) at 00C for 1 hr followed by purification by RP-HPLC and cleavage of the remaining ester and N-trifluoroacetyl groups (0.1 M potassium carbonate in aqueous methanol at 230C for 12 hr). A small amount of hydroquinone was used in this and other deprotection steps. Final purification was conducted with RP-HPLC; RV = 11.0 (9.3 for LTD).
LTD glycine monoamide (LTD glycinamide) (entry 5) was prepared from LTA and N-trifluoroacetylcysteinylglycine amide by the procedure for coupling and deprotection as described (2) ; RV = 12.9.
LTD bisamide (entry 3) was prepared from LTD glycine monoamide by reaction with anhydrous ammonia/ammonium chloride at 25°C for 24 hr; Rv = 7.1.
Deamino LTD (entry 4) bisamide was prepared by LTA methyl ester coupling with 2-mercaptoproponylglycine methyl ester and subsequent reaction with ammonia/ammonium chloride as described; Rv = 9.5.
Deamino LTD (entry 16) was prepared from the intermediate diester of the foregoing synthesis by the usual saponification; Rv= 9.9.
LTD glycine monodimethylamide (LTD dimethylglycinamide) (entry 6) was prepared by coupling of LTA and N-trifluorocysteinylglycine dimethylamide (2) and deprotection as described; Rv = 12.9.
The various dipeptide analogs of LTD (entries 7-14) were prepared similarly from LTA by coupling of the N-trifluoroacetyl methyl ester of the free sulfhydryl dipeptide in methanolic triethylamine (2) , followed by deprotection (2) Reaction of LTD (40 Ag/ml) with 20 equivalents of sodium periodate at pH 6.8 in water containing 20% ethanol at 23TC for 6 hr afforded two diastereomeric sulfoxides (entries 19 and 20), each having an ultraviolet maximum at 1.5-nm-higher wavelength than that of LTD: isomer 2 (more polar) Rv = 6.0; isomer 1 (less polar) Rv 6.5:
6-Epi-LTD (entry 21) and 6-epi-LTG (entry 22) were made as described elsewhere (10); Rv of 6-epi-LTD = 10.7.
5-Epi-LTD (entry 23) was derived from the coupling of the racemic cis epoxide corresponding to LTA with glutathione (forming a mixture of 5-and 6-epi-LTC), cleavage with y-glutamyl transpeptidase and RP-HPLC separation of the resulting mixture of 5-and 6-epi-LTD; Rv of 5-epi-LTD = 11.5.
5-Dehydroxy-9-12, 14,15-hexahydro-LTD (entry 24) (together with the C-6 epimer) was synthesized by coupling methyl 6-tosyloxy-eicosa-cis-11,12-enoate with N-trifluoroacetylcysteinylglycine methyl ester followed by deprotection by base (2) .
Biological Measurements. Pulmonary parenchymal strips were prepared for the recording of isometric contractile activity (11) at an initial tension of 1.0 g and allowed to relax to a baseline tension of approximately 250 mg. A concentration-effect relationship for histamine (obtained as diphosphate from Sigma) was then determined for each tissue, and assays for activity of leukotriene analogs were carried out on those tissues that had achieved net active tensions of at least 12 mg and 225 mg after exposure to 0.1 and 100 ,uM histamine solutions, respectively. The tissues to be used were washed three times with saline and allowed to return to their baseline tensions. A concentrationeffect curve was determined 30-90 min later with LTC, LTD, or a structural analog used as the contractile agonist. Each structural analog was assessed for contractile activity on 4-16 guinea pig pulmonary parenchymal strips. Tachyphylaxis of the pulmonary parenchymal strips prevented concentration-effect testing of more than one compound on the same tissue strip. Data were expressed as a percentage of the active tension elicited by 100 ,M histamine for each tissue. For the 17 active compounds, the molar concentration ofnaturally-occurring leukotriene or analog required to achieve a response equal in magnitude to 50% of the 100 ,uM histamine response (EC,%) was determined by interpolation from the concentration-effect relationship for each tissue. The substantial variability among parenchymal tissues in the magnitude of the response at low concentrations (0.1-10 pM) of LTD and the lesser variability at the EC50 (8) form the basis for the use ofthe EC5o as the major index of comparison among LTC (EC,% = 10 nM), LTD (EC50 = 0.6 nM), and the more active of the analogs. Comparison of the EC5o of the analog to that of LTD yielded an EC50 ratio, and the quantities of analogs available allowed ratios as low as 0.001 to be determined; inactive analogs are described by activity ratios of less than 0.001. Whenever an analog presented a twophase dose-response curve similar to that of LTD (6, 7), it was recorded.
The guinea pig ileum bioassay was prepared as described (3). The response of the ileum to LTD was linear in the concentration range of 0.2-0.8 nM and corresponded to responses in the histamine concentration range from 5-20 ng/ml (40-160 nM). Because LTC effects on the ileum persisted in a slowly decreasing degree, despite repeated washing, this compound was not utilized for standardization of responses. The responses to 0.2, 0.4, and 0.8 nM LTD were assayed before and after testing each analog on an ileum preparation. Ileum preparations did not show tachyphylaxis, and, thus, each tissue preparation was Table 1. used to test up to four compounds. Each analog was assessed on at least two ileum preparations and available quantities of the analogs allowed activity ratios versus LTD as low as 0.002 to be accurately determined.
RESULTS
The mean contractile effects of LTC, LTD, and LTE on guinea pig pulmonary parenchymal strips are shown in Fig. 2a for ref- erence to the actions of structural analogs. The low-slope and high-slope portions of the LTD and LTE dose-response curves are apparent. The activities of the various leukotriene analogs in both pulmonary parenchymal strip and ileum bioassays are summarized in Table 1 .
Peptide Modification. Replacement of an amino acid in the peptide part of LTD or LTE by another amino acid, as studied for nine synthetic analogs (Table 1 , entries 7-15), generally resulted in a 1-3 orders of magnitude decrement in contractile activity; none of the analogs exhibited enhanced activity compared to the natural leukotriene parent. The analogs in which the glycine unit of LTD was replaced by D-alanine or L-alanine (entries 7 and 8) or those in which the L-cysteine unit was replaced by D-cysteine or L-homocysteine (entries 14 and 12) still showed substantial activity. More dramatic attenuation of activity was observed upon replacement ofglycine by valine (entry 11), glutamic acid (entry 10), or proline (entry 9). The substitution ofpen for cysteine in either LTD (entry 13) or LTE (entry 15) resulted in a loss ofactivity by 3 orders ofmagnitude or more (Fig. 2b) . (Fig. 2c) . Nacetyl-LTE retained 31% of activity relative to LTE on the pulmonary strip and 57% on the ileum. Deamino LTD had a dose ratio of 0.20 for the ileum relative to LTD, whereas deamino LTD bisamide, and LTD bisamide (entries 4 and 3) were essentially inactive.
Oxidation Level at the C-6-Linked Sulfur. The two sulfoxides of LTD differed greatly from one another in spasmogenic activities for either assay tissue. Whereas the less polar sulfoxide (isomer 1, entry 19) was 10% as active as LTD on the pulmonary parenchymal strip and on the ileum, the more polar sulfoxide (isomer 2, entry 20) was less than 0.1% as active on both assays (Fig. 2d) .
Chirality at C-5 and C-6. The 5(S)-hydroxy-6(S)-cysteinylglycyl isomer of LTD (6-epi-LTD, entry. 21) and 5(R)-hydroxy-6(R)-cysteinylglycyl isomer of LTD (5-epi-LTD, entry 23) each had EC,% ratios of 0.004 on the pulmonary parenchymal strips, and retained a low-slope initial response phase (Fig. 2d ). An equivalent loss of activity relative to LTD was apparent on the ileum assay. The 6-epimer ofLTC (entry 22) retained substantial activity (8-10%) on both assays relative to LTC. Whereas 5-hydroxyl-9,12,14,15-hexahydro-LTD had an EC50 of 0.019 on the pulmonary parenchymal strip and a dose ratio of 0.005 on the ileum (8) (8) . The other criteria, saturability and a dose-dependent relationship of binding to the functional response, have yet to be addressed. Based upon these data and those in a previous communication (8) , we hypothesize that the pulmonary parenchyma of the guinea pig may possess a true receptor for LTD, which is comprised of both (i) a loose hydrophobic binding site, accepting the w portion ofthe eicosanoid; and (ii) a complex active site, accommodatingthe C-1 carboxyl group in-the nonionized form, the C-5 hydroxyl group, and a peptide part having a nonprotonated amino function. It would seem that the stereo relationship between the eicosanoid.and peptide portions is not rigidly set but that.one or more optimal relative arrangements -exist.
The foundation is now in place for a more intimate probing of the structure-activity relationships for SRS-As and a better understanding of their binding and molecular function.
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